Sharps Technology (STSS) Competitors

$1.80 -0.08 (-4.26%)

Closing price 04:00 PM Eastern

Extended Trading

$1.80 0.00 (0.00%)

As of 04:10 PM Eastern

STSS vs. SGHT, TLSI, SI, PROF, and CARL

Should you buy Sharps Technology stock or one of its competitors? MarketBeat compares Sharps Technology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sharps Technology include Sight Sciences (SGHT), TriSalus Life Sciences (TLSI), Shoulder Innovations (SI), Profound Medical (PROF), and Carlsmed (CARL). These companies are all part of the "medical equipment" industry.

How does Sharps Technology compare to Sight Sciences?

Sight Sciences (NASDAQ:SGHT) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.

Sharps Technology has a net margin of 0.00% compared to Sight Sciences' net margin of -46.83%. Sight Sciences' return on equity of -52.34% beat Sharps Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sight Sciences	-46.83%	-52.34%	-28.49%
Sharps Technology	N/A	-157.91%	-154.40%

Sight Sciences currently has a consensus target price of $8.31, suggesting a potential upside of 71.04%. Given Sight Sciences' stronger consensus rating and higher probable upside, equities analysts clearly believe Sight Sciences is more favorable than Sharps Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sight Sciences	1 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.44
Sharps Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

55.5% of Sight Sciences shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 28.9% of Sight Sciences shares are owned by company insiders. Comparatively, 1.2% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Sharps Technology had 3 more articles in the media than Sight Sciences. MarketBeat recorded 7 mentions for Sharps Technology and 4 mentions for Sight Sciences. Sight Sciences' average media sentiment score of 1.02 beat Sharps Technology's score of 0.56 indicating that Sight Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sight Sciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sharps Technology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Sight Sciences has higher revenue and earnings than Sharps Technology. Sight Sciences is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sight Sciences	$77.36M	3.42	-$38.43M	-$0.71	N/A
Sharps Technology	$200K	380.88	-$282.50M	-$831.52	N/A

Sight Sciences has a beta of 2.38, meaning that its stock price is 138% more volatile than the broader market. Comparatively, Sharps Technology has a beta of 2.03, meaning that its stock price is 103% more volatile than the broader market.

Summary

Sight Sciences beats Sharps Technology on 12 of the 16 factors compared between the two stocks.

How does Sharps Technology compare to TriSalus Life Sciences?

TriSalus Life Sciences (NASDAQ:TLSI) and Sharps Technology (NASDAQ:STSS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, profitability, analyst recommendations, institutional ownership, earnings, valuation and dividends.

In the previous week, TriSalus Life Sciences and TriSalus Life Sciences both had 7 articles in the media. Sharps Technology's average media sentiment score of 0.56 beat TriSalus Life Sciences' score of -0.05 indicating that Sharps Technology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TriSalus Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Sharps Technology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive

Sharps Technology has a net margin of 0.00% compared to TriSalus Life Sciences' net margin of -60.85%. TriSalus Life Sciences' return on equity of 0.00% beat Sharps Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TriSalus Life Sciences	-60.85%	N/A	-69.91%
Sharps Technology	N/A	-157.91%	-154.40%

TriSalus Life Sciences currently has a consensus target price of $7.50, suggesting a potential upside of 147.52%. Given TriSalus Life Sciences' stronger consensus rating and higher possible upside, equities research analysts clearly believe TriSalus Life Sciences is more favorable than Sharps Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TriSalus Life Sciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sharps Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

TriSalus Life Sciences has higher revenue and earnings than Sharps Technology. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TriSalus Life Sciences	$45.15M	4.11	-$39.23M	-$1.41	N/A
Sharps Technology	$200K	380.88	-$282.50M	-$831.52	N/A

TriSalus Life Sciences has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, Sharps Technology has a beta of 2.03, indicating that its stock price is 103% more volatile than the broader market.

2.6% of TriSalus Life Sciences shares are owned by institutional investors. Comparatively, 17.2% of Sharps Technology shares are owned by institutional investors. 16.3% of TriSalus Life Sciences shares are owned by company insiders. Comparatively, 1.2% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

TriSalus Life Sciences beats Sharps Technology on 9 of the 15 factors compared between the two stocks.

How does Sharps Technology compare to Shoulder Innovations?

Sharps Technology (NASDAQ:STSS) and Shoulder Innovations (NYSE:SI) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, earnings, media sentiment, institutional ownership, analyst recommendations, profitability, dividends and risk.

In the previous week, Shoulder Innovations had 2 more articles in the media than Sharps Technology. MarketBeat recorded 9 mentions for Shoulder Innovations and 7 mentions for Sharps Technology. Sharps Technology's average media sentiment score of 0.56 beat Shoulder Innovations' score of 0.35 indicating that Sharps Technology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sharps Technology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Shoulder Innovations	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Sharps Technology has a net margin of 0.00% compared to Shoulder Innovations' net margin of -81.78%. Shoulder Innovations' return on equity of -35.11% beat Sharps Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-157.91%	-154.40%
Shoulder Innovations	-81.78%	-35.11%	-20.58%

17.2% of Sharps Technology shares are held by institutional investors. 1.2% of Sharps Technology shares are held by company insiders. Comparatively, 29.0% of Shoulder Innovations shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Shoulder Innovations has higher revenue and earnings than Sharps Technology. Shoulder Innovations is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	$200K	380.88	-$282.50M	-$831.52	N/A
Shoulder Innovations	$47.32M	6.48	-$40.36M	-$166.96	N/A

Shoulder Innovations has a consensus target price of $21.00, indicating a potential upside of 42.10%. Given Shoulder Innovations' stronger consensus rating and higher possible upside, analysts clearly believe Shoulder Innovations is more favorable than Sharps Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Shoulder Innovations	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Summary

Shoulder Innovations beats Sharps Technology on 10 of the 15 factors compared between the two stocks.

How does Sharps Technology compare to Profound Medical?

Sharps Technology (NASDAQ:STSS) and Profound Medical (NASDAQ:PROF) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings, valuation and media sentiment.

In the previous week, Sharps Technology had 4 more articles in the media than Profound Medical. MarketBeat recorded 7 mentions for Sharps Technology and 3 mentions for Profound Medical. Profound Medical's average media sentiment score of 0.82 beat Sharps Technology's score of 0.56 indicating that Profound Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sharps Technology	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Profound Medical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

17.2% of Sharps Technology shares are owned by institutional investors. Comparatively, 47.9% of Profound Medical shares are owned by institutional investors. 1.2% of Sharps Technology shares are owned by company insiders. Comparatively, 1.5% of Profound Medical shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Profound Medical has a consensus target price of $12.00, indicating a potential upside of 74.17%. Given Profound Medical's stronger consensus rating and higher probable upside, analysts plainly believe Profound Medical is more favorable than Sharps Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Profound Medical	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Sharps Technology has a beta of 2.03, suggesting that its share price is 103% more volatile than the broader market. Comparatively, Profound Medical has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Profound Medical has higher revenue and earnings than Sharps Technology. Profound Medical is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	$200K	380.88	-$282.50M	-$831.52	N/A
Profound Medical	$16.10M	15.55	-$42.57M	-$1.24	N/A

Sharps Technology has a net margin of 0.00% compared to Profound Medical's net margin of -206.76%. Profound Medical's return on equity of -78.88% beat Sharps Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-157.91%	-154.40%
Profound Medical	-206.76%	-78.88%	-64.06%

Summary

Profound Medical beats Sharps Technology on 11 of the 16 factors compared between the two stocks.

How does Sharps Technology compare to Carlsmed?

Sharps Technology (NASDAQ:STSS) and Carlsmed (NASDAQ:CARL) are both small-cap medical equipment companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, institutional ownership, risk, profitability, analyst recommendations and dividends.

In the previous week, Sharps Technology had 6 more articles in the media than Carlsmed. MarketBeat recorded 7 mentions for Sharps Technology and 1 mentions for Carlsmed. Carlsmed's average media sentiment score of 1.89 beat Sharps Technology's score of 0.56 indicating that Carlsmed is being referred to more favorably in the news media.

Company	Overall Sentiment
Sharps Technology	Positive
Carlsmed	Very Positive

Carlsmed has higher revenue and earnings than Sharps Technology. Carlsmed is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sharps Technology	$200K	380.88	-$282.50M	-$831.52	N/A
Carlsmed	$50.51M	5.88	-$29.63M	-$2.51	N/A

Sharps Technology has a net margin of 0.00% compared to Carlsmed's net margin of -57.76%. Carlsmed's return on equity of -60.74% beat Sharps Technology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sharps Technology	N/A	-157.91%	-154.40%
Carlsmed	-57.76%	-60.74%	-29.84%

Carlsmed has a consensus target price of $19.33, indicating a potential upside of 76.88%. Given Carlsmed's stronger consensus rating and higher possible upside, analysts plainly believe Carlsmed is more favorable than Sharps Technology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sharps Technology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Carlsmed	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

17.2% of Sharps Technology shares are owned by institutional investors. 1.2% of Sharps Technology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Carlsmed beats Sharps Technology on 9 of the 15 factors compared between the two stocks.

Get Sharps Technology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STSS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

STSS vs. The Competition

Export

Metric	Sharps Technology	MED PRODUCTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$76.18M	$8.23B	$6.24B	$12.22B
Dividend Yield	N/A	2.54%	2.80%	5.30%
P/E Ratio	0.00	15.99	20.67	25.27
Price / Sales	380.88	8.16	546.89	70.80
Price / Cash	N/A	16.74	27.48	37.27
Price / Book	0.20	3.58	9.67	6.64
Net Income	-$282.50M	$224.05M	$3.56B	$335.32M
7 Day Performance	-13.88%	-2.39%	-1.85%	-1.77%
1 Month Performance	-5.76%	-3.14%	-2.57%	-1.10%
1 Year Performance	-60.61%	1.01%	31.27%	28.31%

Sharps Technology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
STSS Sharps Technology	0.6791 of 5 stars	$1.80 -4.3%	N/A	-58.9%	$76.18M	$200K	N/A	3	Earnings Report Analyst Downgrade
SGHT Sight Sciences	4.338 of 5 stars	$4.93 -7.2%	$8.31 +68.6%	+40.3%	$288.92M	$77.36M	N/A	210
TLSI TriSalus Life Sciences	1.9867 of 5 stars	$4.56 +0.4%	$7.00 +53.5%	-47.9%	$278.33M	$45.15M	N/A	106
SI Shoulder Innovations	4.0412 of 5 stars	$13.36 +1.0%	$21.00 +57.2%	N/A	$274.02M	$47.32M	N/A	61	Earnings Report
PROF Profound Medical	1.6825 of 5 stars	$7.14 -1.5%	$12.00 +68.1%	+48.0%	$263.45M	$16.10M	N/A	150

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:STSS) was last updated on 5/18/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sharps Technology (STSS) Competitors

STSS vs. SGHT, TLSI, SI, PROF, and CARL

How does Sharps Technology compare to Sight Sciences?

Summary

How does Sharps Technology compare to TriSalus Life Sciences?

Summary

How does Sharps Technology compare to Shoulder Innovations?

Summary

How does Sharps Technology compare to Profound Medical?

Summary

How does Sharps Technology compare to Carlsmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STSS vs. The Competition

Sharps Technology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sharps Technology (STSS) Competitors

STSS vs. SGHT, TLSI, SI, PROF, and CARL

How does Sharps Technology compare to Sight Sciences?

Is SGHT or STSS more profitable?

Do analysts recommend SGHT or STSS?

Do insiders & institutionals hold more shares of SGHT or STSS?

Does the media prefer SGHT or STSS?

Which has stronger valuation and earnings, SGHT or STSS?

Which has more risk and volatility, SGHT or STSS?

Summary

How does Sharps Technology compare to TriSalus Life Sciences?

Does the media refer more to TLSI or STSS?

Is TLSI or STSS more profitable?

Do analysts prefer TLSI or STSS?

Which has preferable valuation and earnings, TLSI or STSS?

Which has more risk & volatility, TLSI or STSS?

Do institutionals & insiders hold more shares of TLSI or STSS?

Summary

How does Sharps Technology compare to Shoulder Innovations?

Does the media favor STSS or SI?

Is STSS or SI more profitable?

Do institutionals and insiders believe in STSS or SI?

Which has better earnings and valuation, STSS or SI?

Do analysts prefer STSS or SI?

Summary

How does Sharps Technology compare to Profound Medical?

Does the media prefer STSS or PROF?

Do insiders and institutionals have more ownership in STSS or PROF?

Do analysts rate STSS or PROF?

Which has more risk and volatility, STSS or PROF?

Which has stronger earnings and valuation, STSS or PROF?

Is STSS or PROF more profitable?

Summary

How does Sharps Technology compare to Carlsmed?

Does the media prefer STSS or CARL?

Which has preferable earnings & valuation, STSS or CARL?

Is STSS or CARL more profitable?

Do analysts prefer STSS or CARL?

Do insiders & institutionals believe in STSS or CARL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

STSS vs. The Competition

Sharps Technology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools